30 closest matches · ranked by relevance
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
COVID-19 · SARS-CoV-2 Infection · Corona Virus Infection
Primary: Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs) — 3; 4; 3; 5 Participants
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
Covid19
Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants
Influenza · COVID-19
Primary: Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity — 74.7; 59.1 Percentage of…
Covid19
Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…
COVID-19 · COVID-19 Immunisation
Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
COVID-19
Primary: Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 2; 1; 1; 0 Participants
Solid Tumor Malignancy · Hematologic Malignancy · Leukemia
Primary: Number of Participants With Grades 1-5 Solicited (Expected) and/or Unsolicited (Unexpected) Adverse Events (AE's): Initial Phase — 0; 0; 1; 0 Participants
SARS-CoV-2 · COVID-19
Primary: Part A: Geometric Mean Titer (GMT) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein — 1266.7; 1786.9; 2122.1; 2218.6 Titers
COVID-19 (Healthy Volunteers)
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1 — 5.00; 5.00; 5.00; 5.00 titers
COVID-19
Primary: Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups. — 4.57; 3.61; 3.78; 3.87 fold rise
SARS-CoV-2
Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001
Papillomavirus Infections · Coronavirus Disease (COVID-19)
Primary: Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV) — 2198.5; 1806.8; 1517.6; 1138.2 mMU/mL
Quality of Life · Injection Site Reaction · Adverse Drug Event
Primary: Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both…
Multiple Myeloma
Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
COVID-19 Disease · SARS Pneumonia · Pneumonia, Viral
Primary: Solicited Adverse Events — 88.0; 68.0; 88.0; 80.0 percent of participants
Vaccination Refusal · COVID-19 Pandemic
Primary: Changes in County-Level Covid-19 Vaccination Measured by Inverse Hyperbolic Sine — 0; -0.023; -0.007; -0.037 asinh(new dose 1s of vaccine)
COVID-19 Vaccination
Primary: Receipt of Any Dose COVID-19 Vaccination — 57621; 65407 Participants — p=0.202
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
SARS-CoV-2 · Influenza
Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Influenza, Human · SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination — 56.3; 11.9; 59.0; 38.5 Percentage of participants
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA — 10.0; 4.0; 5.8; 5.4 Percentage of participants
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic ARs — 270; 554; 113; 290 Participants